Zoledronate
Administration
- Type: Bisphosphonate
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names:
Adult Dosing
- 4mg IV once, may repeat in 7d
Pediatric Dosing
Safety/efficacy not established
Special Populations
Pregnancy Rating
- Pregnancy category D
Lactation risk
- No information available, avoid use or breastfeeding
Renal Dosing
- Adult:
- CrCl 50-60 mL/min: 3.5 mg
- CrCl 40-49 mL/min: 3.3 mg
- CrCl 30-39 mL/min: 3 mg
- CrCl <30 mL/min: Not recommended
Hepatic Dosing
Safety/efficacy not established
Contraindications
- Allergy to class/drug
- Hypocalcemia
- Severe renal impairment (CrCl <35 mL/min or evidence of acute renal impairment)
- Rehydrate hypovolemic patients prior to administration
Adverse Reactions
Serious
- Hypocalcemia
- Bronchoconstriction if aspirin-sensitive asthma
- Osteonecrosis (usually of jaw)
- Acquired fanconi syndrome
- Hypotension
Common
- Bone pain, arthralgia
- Nausea/vomiting, constipation, diarrhea
- Fever
- Fatigue, insomnia, anxiety
- Anemia
- Dyspnea
- Headache, dizziness
- UTI
- Hypophosphatemia, hypokalemia, hypomagnesemia
- Rash
Pharmacology
- Half-life: 146h
- Metabolism: Not metabolized
- Excretion: Urinary
Mechanism of Action
- Acts on osteoclasts to inhibit bone resorption
Comments
See Also
References
https://reference.medscape.com/drug/reclast-zometa-zoledronic-acid-342858#10